- Home
- BYM vs ATAI Comparison
BYM vs ATAI Comparison
Compare BYM & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYM
- ATAI
- Stock Information
- Founded
- BYM 2002
- ATAI 2018
- Country
- BYM United States
- ATAI Germany
- Employees
- BYM N/A
- ATAI N/A
- Industry
- BYM Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- BYM Finance
- ATAI Health Care
- Exchange
- BYM Nasdaq
- ATAI Nasdaq
- Market Cap
- BYM 270.7M
- ATAI 282.6M
- IPO Year
- BYM N/A
- ATAI 2021
- Fundamental
- Price
- BYM $10.62
- ATAI $1.41
- Analyst Decision
- BYM
- ATAI Strong Buy
- Analyst Count
- BYM 0
- ATAI 3
- Target Price
- BYM N/A
- ATAI $10.50
- AVG Volume (30 Days)
- BYM 60.2K
- ATAI 1.4M
- Earning Date
- BYM 01-01-0001
- ATAI 05-19-2025
- Dividend Yield
- BYM 4.49%
- ATAI N/A
- EPS Growth
- BYM N/A
- ATAI N/A
- EPS
- BYM N/A
- ATAI N/A
- Revenue
- BYM N/A
- ATAI $308,000.00
- Revenue This Year
- BYM N/A
- ATAI $65.58
- Revenue Next Year
- BYM N/A
- ATAI N/A
- P/E Ratio
- BYM N/A
- ATAI N/A
- Revenue Growth
- BYM N/A
- ATAI N/A
- 52 Week Low
- BYM $9.30
- ATAI $1.03
- 52 Week High
- BYM $11.77
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- BYM 52.34
- ATAI 44.57
- Support Level
- BYM $10.46
- ATAI $1.36
- Resistance Level
- BYM $10.63
- ATAI $1.54
- Average True Range (ATR)
- BYM 0.13
- ATAI 0.09
- MACD
- BYM 0.04
- ATAI -0.00
- Stochastic Oscillator
- BYM 91.82
- ATAI 0.00
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.